SCHEMBL2804205

SCHEMBL2804205

CN(C)CCCN1CCN(C(=O)N2CCc3c(cnc4[nH]ncc34)C2)CC1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMYD2 Q9NRG4 6/20 0.36
HSP90AA1 P07900 2/20 0.35
JAK3 P52333 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
GSK3B P49841 1/20 0.33
BDKRB1 P46663 1/20 0.33
ACHE P22303 1/20 0.33
GRIN2B Q13224 1/20 0.33
P2RX7 Q99572 1/20 0.33
HSP90B1 P14625 1/20 0.32
PLK1 P53350 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
SYK P43405 1/20 0.32
CFTR P13569 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12316273 0.77 ENPP2 (0.43)
SCHEMBL2808014 0.77 ALOX15 (0.40)
SCHEMBL2805094 0.76 PLAT (0.33) HSP90AA1GSK3BHRH3
SCHEMBL2803011 0.76 FAAH (0.45) JAK3ACHE
SCHEMBL2804093 0.74 NAMPT (0.51)
SCHEMBL2804250 0.74 KMT2A (0.41)
SCHEMBL2803239 0.72 PRMT5 (0.38)
SCHEMBL2486452 0.72 NR1H2 (0.51)
SCHEMBL2486314 0.72 NAMPT (0.46)
SCHEMBL2802864 0.71 KIT (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 SMYD2 1884/4885HSP90AA1 2867/4885JAK3 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.